James N Wilson sold $1.1M of CORT
director at CORCEPT THERAPEUTICS INC. 10,000 shares at an average of $110.69, traded Sep 15, 2026, filed Sep 16, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 0.9% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-393124, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | SOpen-market sale Common Stockindirect: James N. Wilson and Pamela D. Wilson Trust10b5-1 | -6,800 | $110.27 | $750k | 1,067,743 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stockindirect: James N. Wilson and Pamela D. Wilson Trust10b5-1 | -400 | $110.84 | $44k | 1,067,343 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stockindirect: James N. Wilson and Pamela D. Wilson Trust10b5-1 | -2,800 | $111.70 | $313k | 1,064,543 | 26 d ago |
Related signals
Other insiders at CORCEPT THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -242% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.2M 10,000 shares | -154% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $967k 8,333 shares | -68% | |
| 20Weak | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $30k 296 shares | -7% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.1M 10,000 shares | -64% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $6.5M 58,333 shares | -93% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -72% | |
| 30Weak | CORCEPT THERAPEUTICS INC | Joseph K Belanoff Chief Executive Officer | $1.3M 26,198 shares | -1% | |
| 61Notable | CORTbuy CORCEPT THERAPEUTICS INC | G Leonard Baker Jr director | $3.3M 100,000 shares | +10% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Joseph K Belanoff Chief Executive Officer | $3.2M 40,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.